

June 25, 2026

To, <b>National Stock Exchange of India Limited,</b> “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, <b>BSE Limited,</b> Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
<b>NSE Symbol: GLENMARK</b>	<b>BSE Scrip Code: 532296</b>
<b>ISIN: INE935A01035</b>	<b>ISIN: INE935A01035</b>
<b>Our Reference No. 25/26-27</b>	<b>Our Reference No. 25/26-27</b>

Dear Sir/ Madam,

**Sub: Intimation of Schedule of Analyst / Institutional Investor Meeting**

Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform the details of Analyst / Institutional Investor meeting to be conducted as under:

<b>Date</b>	<b>Analyst/Institutional Investors/Event</b>	<b>Venue</b>	<b>Type of Meeting</b>	<b>Group / One-on-one</b>
June 30, 2026 to July 01, 2026	Investor meetings	London	Physical	Both

The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these meetings. The schedule of the above-mentioned meetings is subject to change due to exigencies on the part of Investor / Company.

We request you to take this intimation on record.

Thanking You.

**For Glenmark Pharmaceuticals Limited**

**Rashmi Khandelwal**  
**Company Secretary & Compliance Officer**  
**ACS - 28839**

**Glenmark Pharmaceuticals Limited**

Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India

T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com